Friday, September 19, 2014

Roth starts BioBlast Pharma at buy

Roth starts BioBlast Pharma at buy

August 25, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and $15 price target. The stock closed at $7.68 on Friday. BioBlast has three proprietary platform technologies to treat rare and ultra-rare genetic diseases. They include Cabaletta for mutant protein stabilization, BBrm for induction of read-through (bypass) of early mutant DNA stop […]

Lorus hopes to start LOR-253 trial in mid-September

Lorus hopes to start LOR-253 trial in mid-September

August 12, 2014 by · Leave a Comment 

Tweet After a corporate refocusing with a new management and clinical development team, Lorus Therapeutics (OTC:LRUSF; TSX:LOR) plans to begin a Phase 1b clinical trial in mid-September of its LOR-253 drug candidate for the treatment of several blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), which is a pre-malignant type of […]

Roth starts iRadimed at buy

Roth starts iRadimed at buy

August 11, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of iRadimed (NASDAQ:IRMD) with a “buy” rating and $14 price target. The stock finished at $11.03 on Friday. iRadimed’s mRidium 3860+ pump system is a unique MRI-safe, non-magnetic IV infusion pump that offers an effective way to safely and accurately deliver necessary IV fluids to critically ill and […]

Roth starts Sucampo at buy

Roth starts Sucampo at buy

August 1, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Sucampo Pharmaceuticals (NASDAQ:SCMP) with a “buy” rating and price target of $9. The shares were quoted at $6 in early trading on Friday. “Our positive thesis on Sucampo is based on three tenets,” writes analyst Ed Arce. On Aug. 5, new CEO, Peter Greenleaf, will announce his […]

Roth starts Alcobra Pharma at buy

Roth starts Alcobra Pharma at buy

August 1, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Alcobra Pharma (NASDAQ:ADHD) with a “buy” rating and $40 price target. The stock closed at $18.02 on Thursday. Alcobra Pharma’s lead product, MDX, an extended release formulation of Metadoxin, is being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). MDX could also have a significant […]

Roth upgrades Prosensa Therapeutic to buy

Roth upgrades Prosensa Therapeutic to buy

July 28, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded Prosensa Therapeutic NV (NASDAQ:RNA) to “buy,” with a $17 price target, reflecting evolving data in the treatment of Duchenne muscular dystrophy (DMD) and a conciliatory regulatory environment. The stock closed at $9.65 on Friday. Prosensa’s drisapersen treatment for DMD failed a Phase 3 trial last fall, prompting partner GlaxoSmithKline […]

Roth starts CorMedix at buy

Roth starts CorMedix at buy

July 24, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and $3 price target. The stock closed at $1.94 on Wednesday. “The impetus for our buy rating is the potential of the company’s Neutrolin compound to drive revenues and ultimately profits,” writes analyst Scott Henry. Neutrolin is approved in Europe and […]

Roth starts PTC Therapeutics at buy

Roth starts PTC Therapeutics at buy

July 7, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “buy” rating and $34 price target. The stock was quoted at $26.04 at mid-day on Monday. PTC is pioneering the development of small molecules for the treatment of rare genetic disorders and other chronic conditions. “The conditional approval for ataluren in the […]

Roth ups EnteroMedics price target to $5

Roth ups EnteroMedics price target to $5

June 18, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” EnteroMedics (NASDAQ:ETRM) to $5 from $3 after the FDA’s Gastroenterology-Urology Device Advisory Panel voted that the benefits of the company’s Maestro System outweigh the risks by a margin of six-to-two, with one abstention. Shares of EnteroMedics closed at $1.52 on Tuesday. On safety, the […]

Roth ups TG Therapeutics target to $20

Roth ups TG Therapeutics target to $20

June 16, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” TG Therapeutics (NASDAQ:TGTX) to $20 from $15 after the company announced data from its Phase 2 study of TG-1101 & ibrutinib combination in r/r CLL or MCL. The stock closed at $8.82 on Friday. The first ten evaluable patients demonstrated an ORR of 90% […]

Next Page »

Email Newsletters with Constant Contact
Google+